Celltech profits delay
Thursday 29 May 1997
However, Peter Fellner, chief executive, said the group's follow up treatment for the bowel condition, Crohn's disease, would replace at least a third of the value the company had lost after it was forced last week to abandon the sepsis drug, which was being developed in partnership with Bayer.
Dr Fellner said Bayer had returned the rights to the Crohn's disease drug and that Celltech had begun discussions with companies specialising in the gastrointestinal field.
He said that he expected to sign up a licencing partner on more favourable terms than with Bayer. "Septic shock was first, second and third on Bayer's list of priorities. Bayer had only agreed to develop the Crohn's drug on condition that the sepsis drug worked."
Dr Fellner said that pivotal trial data on the group's leukaemia drug being developed with American Home Products was expected this year.
The group said that the value would also come from other more early stage drugs including a new approach to the treatment of asthma. Dr Fellner said that the group had five or six years cash left at current burn rates. He added that the septic shock episode validated the group's strategy. "You can't run a pure biotech with low risk products and we do have high risk and innovative drugs. But we try to balance that with a low risk financial strategy, by having major partners who take on the costs of research."
Results for the six months to 31 March, announced yesterday, showed that the group had pounds 41m cash. Underlying losses rose from pounds 5m to pounds 5.9m after research costs climbed pounds 1.5m higher to pounds 10m.
The group's shares, which were over 600p before last week's announcement, firmed 4.5p to 338.5p.
- 1 Rarest Beanie Baby bought for just £10 at car boot sale could be sold for £62,500 on eBay
- 2 Katie Hopkins and The Sun editor David Dinsmore reported to police for incitement to racial hatred following migrant boat column
- 3 Giorgio Armani criticises the way some gay men dress saying 'a man has to be a man'
- 4 Rebecca Francis accuses Ricky Gervais of using 'influence' to target female hunters after receiving barrage of death threats
- 5 Australian student Tommy Connolly, 23, adopts his pregnant, homeless 17-year-old cousin to give her a chance at 'a better life'
Rarest Beanie Baby bought for just £10 at car boot sale could be sold for £62,500 on eBay
Katie Hopkins and The Sun editor David Dinsmore reported to police for incitement to racial hatred following migrant boat column
'Jihadi John': Isis executioner Mohammed Emwazi wanted to wage jihad in Somalia until his friends were betrayed and killed by al-Shabaab
Parma, Missouri: 80 per cent of town's police quit after first black mayor is elected
Australian student Tommy Connolly, 23, adopts his pregnant, homeless 17-year-old cousin to give her a chance at 'a better life'
If I’m being racially abused I don’t need a stranger with a saviour complex to rescue me
The only black face in the Ukip manifesto is on the page about overseas aid
Ukip is the only main political party to not address LGBT rights in its manifesto
Food banks: One million Britons will soon be using them, according to Trussell Trust
Religion isn't growing, it is becoming vigorous in its demise, says philosopher AC Grayling
BBC election debate: The one photo that summed up the whole 90-minute leaders debate
iJobs Money & Business
£60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...
£30 - 35k (DOE): Guru Careers: We are seeking a Pricing Analyst with experienc...
£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...
£21000 - £24000 per annum: Ashdown Group: The Ashdown Group has been engaged b...